BioSpace News Archive

Business

Kaléo Adds Chief Business Officer to Executive Team

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, announced the appointment of its new Chief Business Officer.

September 27, 2022
·
1 min read
Pharm Country

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Ovid Therapeutics Inc. today announced that management will present at the Ladenburg Thalmann 2022 Healthcare Conference in New York, New York on Thursday, September 29, 2022, at 9:00 a.m. ET.

September 27, 2022
·
3 min read
BioMidwest

Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.

Nemaura Medical, Inc. announces that it has entered into a preliminary agreement with EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry.

September 27, 2022
·
3 min read
Business

Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics, Inc. and AmerisourceBergen announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).

September 27, 2022
·
8 min read
Pharm Country

PaxMedica, Inc. Provides Corporate Update After IPO

PaxMedica, Inc. provided a corporate update after the Company’s initial public offering, which closed on August 26, 2022.

September 27, 2022
·
5 min read
Drug Development

aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma, Inc. today announced that it has dosed the first patient in the global pivotal EFZO-FIT™ study.

September 27, 2022
·
6 min read
Drug Development

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

atai Life Sciences N.V. announced today its Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.

September 27, 2022
·
8 min read
Business

Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

Akari Therapeutics, Plc today announced financial results for the quarter ended June 30, 2022, as well as pre-clinical and clinical progress on nomacopan and long-acting PAS-nomacopan.

September 27, 2022
·
11 min read
Drug Development

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial

Achieve Life Sciences, Inc. today announced that target enrollment of 750 subjects has been reached in the Phase 3 ORCA-3 trial.

September 27, 2022
·
7 min read
Genetown

TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference

TransCode Therapeutics, Inc. today announced that it will be presenting at the Chardan 6th Annual Genetic Medicines Conference.

September 27, 2022
·
4 min read